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Non-alcoholic fatty liver disease (NAFLD) is the histological
expression of different assaults on the liver, including lipid, glu-
cose abnormalities, and obesity. The injury is indistinguishable
from that caused by alcohol. Susceptibility and natural history
of NAFLD seem to be modulated by gene-environment interac-
tions. However, our current knowledge of the genetic traits
involved in NAFLD is limited. In the current issue of the Journal
of Hepatology, Valenti et al. [1], report a well-powered study on
a large cohort of European patients with biopsy-proven NAFLD
that showed lack of association between apolipoprotein C3
(APOC3) promoter SNPs (T-455C and C-482T) and the severity
of liver damage, even after controlling for PNPLA3 mutation. Apo-
lipoprotein C3 (ApoC3) is a 9 kDa protein inhibitor of lipoprotein
lipase, which modulates the binding of chylomicron remnants
and very-low-density lipoproteins (VLDL) to low-density-lipo-
proteins (LDL) receptors. Lipoprotein lipase hydrolyses triacylgly-
cerols in chylomicrons, VLDL, LDL, and diacylglycerols. Thus,
ApoC3 decreases the uptake of triglyceride-rich particles by liver
cells for subsequent degradation. APOC3, located in the chromo-
some 11, is a good candidate gene because, in the original study
[2], both SNPs were associated with fat deposition in Indian men
despite not having risk factors for hepatic steatosis, and was val-
idated in a similar cohort of non-Asian men. Moreover, APOC3
promoter region polymorphisms C-482T and T-455C were found
to be associated with lipid metabolism and insulin signalling and
previously with metabolic syndrome (MetS) and hypertriglyceri-
daemia [3]. Further conﬁrmation came from a meta-analysis indi-
cating that the functional 455 T>C promoter polymorphism in
APOC3 was associated with an approximately 2-fold increased
risk in MetS [4] (Table 1). Differences in genetic analyses and
methods to deﬁne phenotypes could explain, at least in part, dif-
ferences in results between both studies: (a) Petersen et al. [2]
classiﬁed patients according to content of liver fat using protonJournal of Hepatology 20
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tological analysis of liver biopsies. Fat deposition does not neces-
sarily mean liver disease. Indeed, triglyceride deposition per se is
not directly injurious to hepatocytes, as demonstrated in patients
with abetalipoproteinaemia who have high levels of triglycerides
in the liver but with little or no injury. High high-fat diets in
transgenic mice that overexpress ApoC3 had greater accumula-
tion of liver diacylglycerol and this was associated with hepatic
insulin resistance [5]. Dissociation of liver fat content from ste-
atohepatitis should be borne in mind when using proton MRS
as diagnostic tool for NAFLD. This limitation is the most com-
monly observed when deﬁning phenotypes across the majority
of published studies; (b) Valenti et al. included adult patients
with altered liver function test values, morbidly obese patients,
and children with diabetes or obesity; whereas Petersen et al.
included a well-selected cohort of patients without ‘‘apparent’’
risk factors of NAFLD; (c) Ethnic origin did inﬂuence NAFLD prev-
alence and, thus, the diagnostic accuracy of genetic markers
depends on the race studied. Recent studies conﬁrmed lack of
association between APOC3 promoter polymorphisms and fat
deposition in patients with and without type 2 diabetes mellitus
[6,7]. Of note is that the study by Valenti et al. addressed the her-
itability of NAFLD in 71 Italian trios and reported a marginal
away association. Heritability of fatty liver has been reported as
between 39% and 58%, a range commonly seen in frequent traits
[8], but these promoter polymorphisms appear not to be
implicated.
Several types of genetic studies on NAFLD have been reported
including candidate genes, genome wide association studies
(GWAS), and bioinformatics-based analyses. Initial studies of
association between candidate genes and disease traits increase
the possibility of a subsequent positive replication of the ﬁndings
when odds ratios are >3, the cohort includes >150 individuals per
phenotype trait and meta-analysis would confer further valida-
tion [9]. A long list of candidate genes in NAFLD reaching negative
association has been reported [10,11]. Moreover, the candidate
gene approach does not take into account the interaction
between genetic signals. New genotype research technologies
have provided incontrovertible evidence that genomic variation
in patatin-like phospholipase domain-containing 3 (PNPLA3) or
adiponutrin gene rs738409C>Gpolymorphism located in chromo-
some 22 is associated with fat accumulation in the liver [12].11 vol. 55 j 1184–1186
Table 1. Inﬂuence of two main SNPs in the promoter region of APOC3 in different phenotypes associated with NAFLD. Percentage of fat accumulation in the liver,
steatosis, non-alcoholic steatohepatitis, ﬁbrosis progression, and metabolic syndrome. Odds Ratios (effect), and the corresponding 95% CI limits (lower and upper) and
signiﬁcance (p value) were calculated by comparing fatty liver, NASH, ﬁbrosis >F1, and metabolic syndrome as dichotomized variables segregated according to APOC3
variants. Validation studies conﬁrmed an association between APOC3 polymorphisms and metabolic syndrome but not steatosis, steatohepatitis or ﬁbrosis progression.
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JOURNAL OF HEPATOLOGYA recent meta-analysis conﬁrmed the association of genotype CC
not only with increased risk of steatosis, but also with ﬁbrosis
progression i.e. patients with the CC genotype showed 3.2-fold
higher risk of developing ﬁbrosis [13]. However, no GWAS has
been conducted in biopsy-proven NAFLD patients yet. In addition
to information obtained using genome-wide scans and the candi-
date gene approach, bioinformatic analyses in search of new
genetic markers for NAFLD have yielded negative results [14].
Using several databases, 247 genes were selected and, after
removing 26 due to symbol overlap, 37 genes showed a priority
score >2 based on the data source and OMIM phenotypes. Five
genes remained within the centre of the interactome and showed
5 or more connections with other nodes in the network. These 5
genes (peroxisomal bifunctional enzyme, mitochondrial enoyl-
CoA hydratase, mitochondrial long-chain-speciﬁc acyl-CoA
dehydrogenase, mitochondrial trifunctional enzyme subunit
alpha, and mitochondrial trifunctional enzyme subunit beta),
which are completely different from the list of candidate genes
or genetic signals extracted from genome-wide association
studies, were tested in a cohort of 10,196 patients with different
metabolic disorders. NAFLD was assessed using surrogate quanti-
tative traits, such as waist circumference, serum triglyceride,
fasting insulin, and plasma glucose, but not liver biopsy. No
statistically signiﬁcant associations remained after Bonferroni
corrections.
To better evaluate the contribution of our genes to NAFLD we
need to conduct genome-wide association studies in large
biopsy-proven patient populations. Histological end-points are
preferred because these are better associated with overall prog-
noses in these patients. Histological phenotypes should include
simple steatosis, non-alcoholic steatohepatitis, and ﬁbrosis stage.
Any potential genetic signal would need to clearly segregate
patients according to the presence or absence of these pheno-
types. Indeed, inﬂammation is a major predictor of ﬁbrosis pro-
gression [15] and advanced ﬁbrosis independently predicts
liver-related mortality [16]. However, this task would seem toJournal of Hepatology 2011be further complicated since PNPLA3 I148M did not distinguish
simple steatosis from non-alcoholic steatohepatitis, despite a
strong association with susceptibility and ﬁbrosis progression
[17]. Also, this approach could provide information about new
therapeutic targets for this major cause of chronic liver disease
which, to date, remains without effective treatment. There is still
a considerable gap between genetic discoveries and application
of the ﬁndings to innovative clinical practice. Fortunately, this
‘‘laboratory bench to bedside’’ gap is slowly closing.Conﬂict of interest
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